Taiwan
· Delayed Price · Currency is TWD Lumosa Therapeutics Statistics
Total Valuation
TPEX:6535 has a market cap or net worth of TWD 27.28 billion. The enterprise value is 26.03 billion.
| Market Cap | 27.28B |
| Enterprise Value | 26.03B |
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6535 has 168.90 million shares outstanding. The number of shares has increased by 1.03% in one year.
| Current Share Class | 168.90M |
| Shares Outstanding | 168.90M |
| Shares Change (YoY) | +1.03% |
| Shares Change (QoQ) | -0.73% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 6.45% |
| Float | 89.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 625.80 |
| PB Ratio | 14.92 |
| P/TBV Ratio | 15.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -62.98 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -87.32 |
Financial Position
The company has a current ratio of 6.60, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.60 |
| Quick Ratio | 5.86 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -1,813.64 |
Financial Efficiency
Return on equity (ROE) is -26.98% and return on invested capital (ROIC) is -15.08%.
| Return on Equity (ROE) | -26.98% |
| Return on Assets (ROA) | -13.38% |
| Return on Invested Capital (ROIC) | -15.08% |
| Return on Capital Employed (ROCE) | -20.87% |
| Revenue Per Employee | 1.01M |
| Profits Per Employee | -9.61M |
| Employee Count | 43 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.22 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.59% in the last 52 weeks. The beta is 0.10, so TPEX:6535's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -14.59% |
| 50-Day Moving Average | 179.57 |
| 200-Day Moving Average | 244.22 |
| Relative Strength Index (RSI) | 46.34 |
| Average Volume (20 Days) | 209,670 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPEX:6535 had revenue of TWD 43.59 million and -413.35 million in losses. Loss per share was -2.52.
| Revenue | 43.59M |
| Gross Profit | 21.52M |
| Operating Income | -382.68M |
| Pretax Income | -424.65M |
| Net Income | -413.35M |
| EBITDA | -377.89M |
| EBIT | -382.68M |
| Loss Per Share | -2.52 |
Balance Sheet
The company has 1.27 billion in cash and 12.02 million in debt, giving a net cash position of 1.26 billion or 7.45 per share.
| Cash & Cash Equivalents | 1.27B |
| Total Debt | 12.02M |
| Net Cash | 1.26B |
| Net Cash Per Share | 7.45 |
| Equity (Book Value) | 1.83B |
| Book Value Per Share | 10.97 |
| Working Capital | 1.24B |
Cash Flow
In the last 12 months, operating cash flow was -297.68 million and capital expenditures -450,000, giving a free cash flow of -298.13 million.
| Operating Cash Flow | -297.68M |
| Capital Expenditures | -450,000 |
| Free Cash Flow | -298.13M |
| FCF Per Share | -1.77 |
Margins
| Gross Margin | 49.38% |
| Operating Margin | -877.96% |
| Pretax Margin | -974.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6535 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.03% |
| Shareholder Yield | -1.03% |
| Earnings Yield | -1.52% |
| FCF Yield | -1.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TPEX:6535 has an Altman Z-Score of 104.18.
| Altman Z-Score | 104.18 |
| Piotroski F-Score | n/a |